Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...
Proteins are the tiny machines that keep our cells running, and how long they last in the cell often determines how well they ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating ...
Acurastem received a grant to develop ALS therapies targeting SYF2, a regulator of TDP-43, in collaboration with academic ...
InvestorsHub on MSN
Akari Therapeutics to present ADC research at AACR Annual Meeting 2026
Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for ...
This manuscript explores the dynamic behaviors of Pol II and Pol III puncta that encompass the SL1 and 5S genes, following up on the authors' prior studies on ATTF-6. The authors show that ATTF-6 is ...
PepGen Inc. ( (PEPG)) has shared an update. On March 4, 2026, PepGen Inc. released an updated corporate presentation detailing progress on its EDO platform and lead candidate PGN-EDODM1 for myotonic ...
Dyne Therapeutics' Z-basivarsen led to gains in motor function and cognition for myotonic dystrophy type 1, and is entering a ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results